← Leaderboards
Amy Jo Johnson
Ohio State University
$2,112,180
Attributed
$4,920,419
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2013–17$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$4,920,419 · 3
By mechanism
R01$4,920,419 · 3
Top collaborators
- John C Byrd8 shared
- Jennifer A. Woyach6 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jennifer A. Woyach$6,733,332
- Michael R Grever$17,739,693
- Kristie A Blum$3,505,109
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaSignal PathwayRefractoryReceptor SignalingRelapseResponseProgression-Free SurvivalsPhase 1 StudyReceptors, Antigen, B-CellGenomicsChronic Myeloid LeukemiaMutationChronic Lymphocytic LeukemiaResistancePharmacodynamicsNon-Hodgkin&AposLymph NodesBone MarrowAgammaglobulinaemia Tyrosine KinaseFutureCellsBaseAdult LeukemiaHigh Risk
Grant awards (10)
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$523,187
R01 · FY2017 · CA
Targeted Therapy for Lymphoid Malignancies$536,708
R01 · FY2016 · CA
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$536,570
R01 · FY2016 · CA
Improving BTK Directed Therapy for CLL$352,275
R01 · FY2016 · CA
Targeted Therapy for Lymphoid Malignancies$536,708
R01 · FY2015 · CA
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$527,877
R01 · FY2015 · CA
Improving BTK Directed Therapy for CLL$352,275
R01 · FY2015 · CA
Targeted Therapy for Lymphoid Malignancies$520,184
R01 · FY2014 · CA
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$500,541
R01 · FY2014 · CA
Targeted Therapy for Lymphoid Malignancies$534,094
R01 · FY2013 · CA